137 related articles for article (PubMed ID: 12112325)
1. Preferential enrichment: full crystallographic analysis of the unusual phenomenon in the mixed crystals' version.
Takahashi H; Tamura R; Fujimoto D; Lepp Z; Kobayashi K; Ushio T
Chirality; 2002 Jul; 14(7):541-7. PubMed ID: 12112325
[TBL] [Abstract][Full Text] [Related]
2. Preferential enrichment: an essential crystal structure.
Takahashi H; Tamur R; Lepp Z; Kobayashi K; Ushio T
Enantiomer; 2001; 6(1):57-66. PubMed ID: 11434543
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of preferential enrichment, an unusual enantiomeric resolution phenomenon caused by polymorphic transition during crystallization of mixed crystals composed of two enantiomers.
Tamura R; Fujimoto D; Lepp Z; Misaki K; Miura H; Takahashi H; Ushio T; Nakai T; Hirotsu K
J Am Chem Soc; 2002 Nov; 124(44):13139-53. PubMed ID: 12405843
[TBL] [Abstract][Full Text] [Related]
4. Preferential enrichment: significant influence of minor molecular modification on the mode of polymorphic transition during crystallization.
Fujimoto D; Takahashi H; Ariga T; Tamura R
Chirality; 2006 Feb; 18(3):188-95. PubMed ID: 16432918
[TBL] [Abstract][Full Text] [Related]
5. Separation of non-racemic mixtures of enantiomers: an essential part of optical resolution.
Faigl F; Fogassy E; Nógrádi M; Pálovics E; Schindler J
Org Biomol Chem; 2010 Mar; 8(5):947-59. PubMed ID: 20165781
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a solid solution of enantiomers in a racemate-forming system by seeding.
Huang J; Chen S; Guzei IA; Yu L
J Am Chem Soc; 2006 Sep; 128(36):11985-92. PubMed ID: 16953640
[TBL] [Abstract][Full Text] [Related]
7. Formation of solid solutions between racemic and enantiomeric citalopram oxalate.
de Diego HL; Bond AD; Dancer RJ
Chirality; 2011 May; 23(5):408-16. PubMed ID: 21472783
[TBL] [Abstract][Full Text] [Related]
8. Induction and inhibition of preferential enrichment by controlling the mode of the polymorphic transition with seed crystals.
Tamura R; Mizuta M; Yabunaka S; Fujimoto D; Ariga T; Okuhara S; Ikuma N; Takahashi H; Tsue H
Chemistry; 2006 Apr; 12(13):3515-27. PubMed ID: 16502450
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the phase diagrams of chiral praziquantel.
Liu Y; Wang X; Wang JK; Ching CB
Chirality; 2006 May; 18(4):259-64. PubMed ID: 16521119
[TBL] [Abstract][Full Text] [Related]
10. Study of the characterization and crystallization of 4-hydroxy-2-pyrrolidone.
Wang XJ; Wiehler H; Ching CB
Chirality; 2004 May; 16(4):220-7. PubMed ID: 15034904
[TBL] [Abstract][Full Text] [Related]
11. Unusual Disordered Crystal Structure of a Racemate Exhibiting a Novel Enantiomeric Resolution: Preferential Enrichment.
Tamura R; Takahashi H; Hirotsu K; Nakajima Y; Ushio T; Toda F
Angew Chem Int Ed Engl; 1998 Nov; 37(20):2876-2878. PubMed ID: 29711107
[TBL] [Abstract][Full Text] [Related]
12. Enantiomeric 3-chloromandelic acid system: binary melting point phase diagram, ternary solubility phase diagrams and polymorphism.
Le Minh T; von Langermann J; Lorenz H; Seidel-Morgenstern A
J Pharm Sci; 2010 Sep; 99(9):4084-95. PubMed ID: 20575001
[TBL] [Abstract][Full Text] [Related]
13. Crystal structures of peptide enantiomers and racemates: probing conformational diversity in heterochiral Pro-Pro sequences.
Saha I; Chatterjee B; Shamala N; Balaram P
Biopolymers; 2008; 90(4):537-43. PubMed ID: 18335426
[TBL] [Abstract][Full Text] [Related]
14. Enantiomerically pure and racemic dimethyl{N-[(2-oxidonaphthalen-1-yl-κO)methylidene]valinato-κ2N,O}tin(IV).
Böhme U; Fels S
Acta Crystallogr C; 2013 Jan; 69(Pt 1):44-6. PubMed ID: 23282912
[TBL] [Abstract][Full Text] [Related]
15. [Physicochemical properties of suplatast tosilate racemate and enantiomers].
Ushio T; Endo K; Yamamoto K
Yakugaku Zasshi; 1996 Nov; 116(11):866-75. PubMed ID: 8981830
[TBL] [Abstract][Full Text] [Related]
16. Anion effect on the binary and ternary phase diagrams of chiral medetomidine salts and conglomerate crystal formation.
Choobdari E; Fakhraian H; Peyrovi MH
Chirality; 2014 Mar; 26(3):183-8. PubMed ID: 24574075
[TBL] [Abstract][Full Text] [Related]
17. First 3-D structure determination of a peptide oxazol-5(4H)-one with a chiral protein amino acid in the heterocyclic moiety: an x-ray diffraction analysis of the enantiomeric and racemic Goodman oxazolone.
Crisma M; Valle G; Moretto V; Formaggio F; Toniolo C
Pept Res; 1995; 8(3):187-90. PubMed ID: 7670234
[TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of solid-state nature of 2-chloromandelic acid.
He Q; Zhu J; Gomaa H; Jennings M; Rohani S
J Pharm Sci; 2009 May; 98(5):1835-44. PubMed ID: 18837015
[TBL] [Abstract][Full Text] [Related]
19. Impact of molecular flexibility on double polymorphism, solid solutions and chiral discrimination during crystallization of diprophylline enantiomers.
Brandel C; Amharar Y; Rollinger JM; Griesser UJ; Cartigny Y; Petit S; Coquerel G
Mol Pharm; 2013 Oct; 10(10):3850-61. PubMed ID: 23984951
[TBL] [Abstract][Full Text] [Related]
20. Application of preferential crystallization to resolve racemic compounds in a hybrid process.
Lorenz H; Polenske D; Seidel-Morgenstern A
Chirality; 2006 Nov; 18(10):828-40. PubMed ID: 16917833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
